PHASE-II STUDY OF DAILY ORAL MILTEFOSINE (HEXADECYLPHOSPHOCHOLINE) IN ADVANCED COLORECTAL-CANCER

被引:67
作者
PLANTING, AST
STOTER, G
VERWEIJ, J
机构
[1] Department of Medical Oncology, Rotterdam Cancer Institute, Dr. Daniel den Hoed Kliniek, 3075 EA Rotterdam
关键词
D O I
10.1016/S0959-8049(05)80142-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
34 patients with metastatic colorectal cancer were treated with the ether lipid miltefosine (hexadecylphosphocholine). Most patients received 3 x 50 mg daily, while in 11 patients the dose could be escalated to 4 x 50 mg daily. Nausea and vomiting were the most frequent side-effects occurring in all but 3 patients, nephrotoxicity was observed in 11 patients. Leucocytosis was observed in 24 and thrombocytosis in 17 patients. 28 patients are evaluable for response. 1 patient obtained a partial response of liver metastases for a duration of 8 months. 3 patients had stable disease while 24 progressed during treatment. We conclude that miltefosine in this dose and schedule has limited activity in colorectal cancer.
引用
收藏
页码:518 / 519
页数:2
相关论文
共 6 条
[1]  
DANHAUSER S, 1991, P ASCO, V10, P109
[2]   HEXADECYLPHOSPHOCHOLINE - A NEW AND SELECTIVE ANTITUMOR DRUG [J].
EIBL, H ;
UNGER, C .
CANCER TREATMENT REVIEWS, 1990, 17 (2-3) :233-242
[3]   CHARACTERIZATION OF THE ANTITUMOR-ACTIVITY OF HEXADECYLPHOSPHOCHOLINE (D-18506) [J].
HILGARD, P ;
STEKAR, J ;
VOEGELI, R ;
ENGEL, J ;
SCHUMACHER, W ;
EIBL, H ;
UNGER, C ;
BERGER, MR .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (09) :1457-1461
[4]  
HILGARD P, 1991, P AACR, P32
[5]  
VERWEIJ J, 1991, P AM SOC CLIN ONCOL, V10, P117
[6]  
1979, WHO OFFSET PUBLICATI, V48